Unraveling the Energy Crisis in Immune Cells: A Key to Atherosclerosis
Atherosclerosis, the silent killer lurking in our arteries, has met its match. Two groundbreaking studies, with the University of Eastern Finland at the helm, have unveiled a critical link between immune cell energy metabolism and the progression of this deadly condition.
Atherosclerosis, the buildup of fatty plaques in arteries, is a global health crisis, leading to heart attacks and strokes. While cholesterol has been a focal point, the immune system's role in plaque stability is now under the spotlight. These studies reveal that the availability of energy, specifically the amino acid glutamine, in macrophages, is crucial for plaque stability.
But here's where it gets controversial...
In the first study, published in Nature Metabolism, researchers discovered that macrophages, our body's cleanup crew, rely on glutamine uptake to repair damaged arteries. A specific transporter, SLC7A7, acts as a gateway for glutamine. When this gateway is blocked, macrophages lose their energy, leading to larger, more unstable plaques - a recipe for disaster.
This finding was further supported by human artery samples, highlighting the potential impact on human health. Professor Minna Kaikkonen-Määttä from the University of Eastern Finland suggests that supporting macrophage metabolism could be a future strategy to prevent heart attacks and strokes.
And this is the part most people miss...
The second study, published in Cardiovascular Research, takes us a step closer to clinical applications. By studying macrophages with advanced technologies, researchers identified protein markers like TREM2, FOLR2, and SLC7A7, which could help identify high-risk plaques. These markers could be used for PET imaging, providing a more accurate picture of plaque activity.
Additionally, soluble TREM2 in the blood might distinguish between stable and symptomatic plaques, potentially leading to a blood test for high-risk patients.
These studies reflect an international effort, with contributions from the University of Barcelona and others. The first study was led by Université Côte d'Azur, while the second had the University of Turku as a co-leader.
The future of atherosclerosis management looks promising, but what do you think? Could this be a game-changer in cardiovascular health? Share your thoughts in the comments!
